Andrew Huberman has built one of the internet’s most powerful health audiences by translating science into practical advice on sleep, fitness, hormones, supplements, and longevity.
Now, the Stanford neuroscientist and podcaster is taking a much more direct role in the consumer-health economy he has helped create: Huberman is joining Hims & Hers’ board.
He will also formally advise the company on science and brand marketing and provide separate marketing support through his Huberman Lab podcast.
Asked how the arrangement would affect his coverage, Huberman told Business Insider: “We will never filter information differently because of a brand relationship.”
The pairing brings one of health podcasting’s biggest figures into the boardroom of a telehealth company expanding from hair loss and erectile dysfunction into weight loss, testosterone, preventive care, and peptides. He’ll join other board members, including former Netflix CFO David Wells and former DoorDash CMO Kofi Amoo-Gottfried.
It also ties Huberman, whose podcast and YouTube channel reach millions of health-conscious listeners each month, to one company that can sell many of the treatments he discusses.
Huberman and Hims CEO Andrew Dudum said he will remain free to cover the category broadly.
Huberman’s role comes with a broad and lucrative set of commercial deals.
His annual compensation, disclosed today in an SEC filing, is worth roughly $5.9 million before any short-form advertising work. That includes a $3.5 million annual cash fee, for two years, to advise Hims on science and brand marketing.
Scicomm Media, the company Huberman co-owns, will also receive $5 million a year for up to three years for podcast advertising. Hims estimates Huberman’s personal interest in that deal at roughly $2.1 million a year. He can also earn up to another $1 million per year by making short-form videos for Hims’ paid advertising channels.
He will receive a $300,000 annualized board package (including a cash retainer and equity award), prorated for his initial term. That would place him near the top of Hims’ director pay, in line with former FDA Deputy Commissioner Deb Autor. His multimillion-dollar advisory and media deals, however, put him in a category of his own.
The Andrews bonded over their shared perspectives on healthcare
While Huberman has previously served as an advisor to fitness and sleep brands, his partnership with Hims & Hers is unique — with fiduciary duties and firsthand involvement in the company’s strategy, not just lending scientific or marketing expertise from the outside.
Huberman told Business Insider he first reached out to Dudum through a mutual friend, and the two spent the last six to eight months discussing the future of consumer healthcare.
“We have some overlapping interests,” Huberman said, including bringing the “best healthcare practices to the broadest number of people.”
“Joining the board allows me to do that rather than just only talk about how Hims & Hers can do that,” he added.
On a joint call Monday, both Huberman and Dudum described their shared ambition to make personalized healthcare more accessible. “How do you empower the masses around the globe to feel better and take more agency in their life?” Dudum said.
Huberman said he sees Hims as filling “this enormous gap that’s existed in the middle” between the traditional healthcare system, where patients can struggle to get time and attention, and high-end concierge care.
“The middle 95%” should be able to access personalized care, he said.
Hims is not alone in chasing that middle. A growing group of telehealth companies such as Ro and Midi, longevity clinics, testing startups, and consumer-health brands is trying to turn once-niche services into more mainstream offerings.
Hims has the advantage of a large existing customer base, nearly 3 million, with its own pharmacy and manufacturing infrastructure — and now a health podcaster with a vast audience of millions who is lending his name to its expanding menu of care.
Hims is betting big on optimization — a sticky area of science and regulation
Huberman’s appointment is particularly notable given Hims’ push into buzzy areas of optimization such as testosterone and peptides, a sprawling category that has gone from a niche biohacking obsession to a more mainstream phenomenon in recent months.
Huberman has been one of the most prominent mainstream voices discussing injectable peptides. Dudum, meanwhile, has been building Hims to sell them.
Hims’ peptide ambitions predate both Huberman’s board appointment and the recent HHS move to temporarily make some of the buzziest peptides available by prescription.
The company signed a deal for a California peptide facility at the end of 2024 and announced the acquisition in February 2025. By May, Dudum was telling investors he was following peptide innovation “deeply,” citing potential uses in pain management, recovery, and “generalized longevity.”
The Washington Post/Getty Images
In recent weeks, Hims previewed the coming launch of Peptides+, a section on the website where consumers will be able to access various peptides (once regulatory approval permits) like BPC-157, as well as other popular wellness therapies like NAD+ and vitamin B12.
Huberman said he has no desire to encourage broad use of peptides among people who don’t need them. “I don’t know if somebody without an injury needs BPC and TB-500,” he said.
Still, he added that one of his biggest selling points for joining the Hims board was their plans to control peptide manufacturing from start to finish — as well as their commitment to being at the forefront of the conversation about what peptides can and can’t do for people. “You have to be a channel, not a dam to this kind of information,” he said.
Dudum similarly said the emerging world of personalized health and longevity “needs to be navigated extremely carefully and very cautiously.”
So, will Huberman maintain editorial independence on his podcast?
The Huberman Lab YouTube channel has more than 8 million subscribers, and his health-and-science podcast is regularly among the most popular in its category.
Huberman said his content would continue to cover benefits, risks, and uncertainty across the category. “We will never filter information differently because of a brand relationship,” he said.
He also said Hims had encouraged him to continue providing education independent of “any kind of product or platform.”
He did not specify how each podcast episode, social post, or short clip will disclose his board seat and separate marketing relationship with Hims.
The bet is that Hims can give consumers a more rigorous path through the flood of wellness information. “It really turns people into scientists of themselves,” Huberman said.
The arrangement puts Huberman in the unusual position of advising people on how to navigate the wellness economy while helping market one of its biggest players.
Correction: An earlier version of this story called Kofi Amoo-Gottfried the former DoorDash CFO. Amoo-Gottfried was the former CMO.
